Table 2 Secondary outcomes (fasting) from study
From: Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals
Median (interquartile range) | P-values | ||||
|---|---|---|---|---|---|
0 weeks | 6 weeks | 12 weeks | 0-6 weeks | 6-12 weeks | |
Total cholesterol, mg/dL | 165 (146, 181) | 166 (130, 178) | 173 (146, 184) | 0.18 | 0.0002 |
High density lipoprotein, mg/dL | 45 (39, 57) | 48 (3, -57) | 47 (43, 60) | 0.95 | 0.02 |
Low density lipoprotein, mg/dL | 91 (79, 120) | 83 (70, 102) | 89 (81, 126) | 0.15 | 0.003 |
Triglycerides, mg/dL | 85 (64, 98) | 75 (52, 116) | 81(71, 98) | 0.33 | 0.95 |
C-reactive protein, mg/L | 2.80 (1.3, 4.6) | 2.98 (1.7, 3.4) | 1.91(1.1, 6.3) | 0.47 | 0.96 |
Fasting insulin, μIU/mL | 10.44 (6.89, 22.7) | 9.37 (4.27, 10.26) | 10.48 (6.87, 17.01) | 0.09 | 0.45 |
Glucose, mg/dL | 92 (77, 95) | 88 (76, 97) | 86 (80, 97) | 0.64 | 0.72 |
C-peptide, ng/mL | 3.81 (2.21, 4.35) | 3.05 (2.32, 4.20) | 3.30 (2.15, 4.37) | 0.49 | 0.35 |
Interleukin-6, pg/mL | 2.90 (2.15, 3.92) | 3.06 (2.13, 3.84) | 3.12 (2.64, 4.03) | 0.81 | 0.62 |